Scarica l'app Stockscreener
95.60
0.43%
0.41
Dopo l'orario di chiusura:
95.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte stock (US45337C1027): AI partnership and pipeline keep biopharma story moving - AD HOC NEWS
[144] INCYTE CORP SEC Filing - Stock Titan
Incyte Stock: Analyst Estimates & Ratings - Barchart.com
Incyte partners with Edison Scientific on AI drug discovery - Investing.com
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development - Business Wire
Incyte Corp stock (US45337C1027): Institutional buying draws fresh attention to the biotech group - AD HOC NEWS
Incyte Corporation $INCY Shares Purchased by Northwestern Mutual Wealth Management Co. - MarketBeat
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build - Yahoo Finance
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Baker Bros. Advisors LP Increases Stake in Incyte Corp with Strategic Acquisition - GuruFocus
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies - AD HOC NEWS
Dodge & Cox holds 12.25M Incyte shares (NASDAQ: INCY), a 6.2% stake - Stock Titan
FDA Approves Once-Daily Jakafi XR for Blood Disorders - MyChesCo
Swiss Life Asset Management Ltd Boosts Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Associa - PharmiWeb.com
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress - BioSpace
Incyte to Present Pipeline Strategy at May Investor Conferences - MyChesCo
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Baker Brothers and Incyte (INCY): 15,000-share option exercise detailed - Stock Titan
Baker Bros. funds exercise Incyte (NASDAQ: INCY) director stock options - Stock Titan
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24 - Insider Monkey
Incyte Appoints Suketu Upadhyay as Chief Financial Officer - MyChesCo
Incyte Reports Q1 Revenue Growth as Pipeline Advances - MyChesCo
Incyte's (NASDAQ:INCY) Promising Earnings May Rest On Soft Foundations - Yahoo Finance
Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Receives Favorable Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Does Jakafi XR Approval And Pipeline Progress Change The Bull Case For Incyte (INCY)? - Yahoo Finance
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis - BioSpace
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
Incyte presents 24-week data for ruxolitinib cream in atopic dermatitis - Investing.com
Incyte eczema cream held disease control through 24 weeks - Stock Titan
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 - BioSpace
Incyte (NASDAQ: INCY) grants CFO RSUs, options and performance shares - Stock Titan
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Here's Why Incyte (INCY) is a Strong Growth Stock - Yahoo Finance
Horizon Investments LLC Sells 83,430 Shares of Incyte Corporation $INCY - MarketBeat
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
Incyte Corp. Receives Positive Valuation Adjustment Amid Strong Financial Performance - Markets Mojo
Incyte (INCY) Receives FDA Orphan Designation for Pancreatic Can - GuruFocus
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
H.C. Wainwright Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $135 - Moomoo
New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] - Quantisnow
Australia approves new therapy for transplant patients with chronic GVHD - Stock Titan
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings - Insider Monkey
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
1.19%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):